Showing 21 - 40 results of 102 for search 'A.C. Renate~', query time: 3.92s Refine Results
  1. 21
  2. 22
  3. 23
  4. 24
  5. 25
  6. 26
  7. 27
  8. 28
  9. 29
  10. 30
  11. 31
  12. 32

    How do individuals with mental health disorder and spinal cord injury gain access to participate in voluntary sport groups in Switzerland? by Florence Epiney, Siegfried Nagel, Christopher Klenk

    Published 2025-01-01
    “…The Lancet, 398(10298), 443–455. https://doi.org/10.1016/S0140-6736(21)01164-8 Smith, B., & Sparkes, A. C. (2020). Qualitative research. In G. Tenenbaum & R. …”
    Get full text
    Article
  13. 33

    An interpretable machine learning tool for in-home monitoring of agitation episodes in people living with dementia: a proof-of-concept studyResearch in context by Marirena Bafaloukou, Ann-Kathrin Schalkamp, Nan Fletcher-Lloyd, Alex Capstick, Chloe Walsh, Cynthia Sandor, Samaneh Kouchaki, Ramin Nilforooshan, Payam Barnaghi

    Published 2025-02-01
    “…Key features for identifying agitation included low nocturnal respiratory rate, heightened alertness during sleep, and increased indoor illuminance, as revealed by statistical and feature importance analysis. …”
    Get full text
    Article
  14. 34
  15. 35
  16. 36

    Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database by Xi-Feng Wang, Lu-Ri Bao, Ta-La Hu, Rui-Feng Xu, Wu-Niri Gao, Jing-Yuan Wang, Jian-Rong Zhao, Zhen-Li Fu, Shu-Fang Wang, Yan Meng

    Published 2025-01-01
    “…IntroductionEculizumab is a C5 complement inhibitor approved by the FDA for the targeted treatment of four rare diseases, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and aquaporin-4 immunoglobulin G-positive optic neuromyelitis optica spectrum disorders (AQP4-IgG+NMOSD). …”
    Get full text
    Article
  17. 37
  18. 38
  19. 39
  20. 40